What is this medicine?
IDARUCIZUMAB (eye da roo SIZ ue mab) is used to reverse the blood-thinning effect of dabigatran in emergency situations.
How should I use this medicine?
This medicine is for infusion into a vein. It is given by a health care provider in a hospital or clinic setting.
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
signs and symptoms of a blood clot such as breathing problems; changes in vision; chest pain; severe, sudden headache; pain, swelling, warmth in the leg; trouble speaking; sudden numbness or weakness of the face, arm, or leg
signs and symptoms of low potassium like muscle cramps or muscle pain; chest pain; dizziness; feeling faint or lightheaded, falls; palpitations; breathing problems; or fast, irregular heartbeat
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
What may interact with this medicine?
Interactions are not expected.
What if I miss a dose?
This does not apply.
Where should I keep my medicine?
This drug is given in a hospital or clinic and will not be stored at home.
Keep out of the reach of children.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
hereditary fructose intolerance
an unusual or allergic reaction to idarucizumab, other medicines, sorbitol, foods, dyes, or preservatives
pregnant or trying to get pregnant
What should I watch for while using this medicine?
Your condition will be monitored carefully while you are receiving this medication. You may need blood work done while you are taking this medicine.
NOTE:This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider. Copyright© 2019 Elsevier